Progressive dysexecutive syndrome in Alzheimer’s disease

Takeaway

  • Early-onset progressive dysexecutive syndrome (PDS) with biomarkers for Alzheimer’s disease (AD) should be explored as an atypical clinical phenotype that can be due to AD.

Why this matters

  • Atypical clinical phenotypes of AD without specific diagnostic criteria are often encountered, leading to delayed- or misdiagnosis.

  • Identifying atypical phenotypes might facilitate earlier and accurate diagnosis and treatment, with direct implications for patient outcomes.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.